BioNTech Plans to Address Infectious Diseases on the African Continent
investors.biontech.de
investors.biontech.de
They are planning to produce them there. From what I understand, mRNA vaccine production capabilities seem to be versatile. Swap out the mRNA payload and your facility can produce a whole different vaccine in no time. That would put the continent in a much better position if there is ever the need again to have a new vaccine rapidly produced.
Pfizer/BioNTech have also signed an agreement with South Africa's Biovac Institute for the 'fill and finish' manufacturing of their COVID-19 mRNA vaccine.
It's not nearly enough of course, and no substitute for full-blown IP waivers and technology transfer. In fact you could argue they've been forced into this by the threat of those waivers. But it's not nothing.